Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PA 401

Drug Profile

PA 401

Alternative Names: Glycafilin; PA-04-001; PA-401; Recombinant human CXCL8 mutant

Latest Information Update: 04 Sep 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProtAffin Biotechnologie
  • Class Anti-inflammatories; Antibronchitics; Proteins
  • Mechanism of Action Glycosaminoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Cystic fibrosis; Delayed graft function; Pneumonia; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2013 ProtAffin Biotechnologie has ceased operations
  • 31 Jul 2013 Discontinued - Phase-I for Adult respiratory distress syndrome in United Kingdom (Parenteral)
  • 31 Jul 2013 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top